Clinical Trial Update: A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating FWY003 versus placebo for geographic atrophy secondary to age-related macular degeneration is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• FWY003

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 2 | Status: RECRUITING